Company presentation Full year 2018












SOL Group at a glance

- Founded in 1927, is an Italian based multinational company present in 29 countries with more of 4,000 people employed.
- Two core, separated but integrated and synergic business areas: Technical Gas sector (production, applied research and marketing of pure, medical and industrial gases) and Home-Care service sector (supply of medical products and medical assistance services as well as equipment for home care therapy).
- Two recent businesses: Hydro Energy and Biotechnology.
- · Strong results and sound balance sheet:
 - Over 833 millions € of Total Group revenues in FY2018 (+10.1% FY2017);
 - Over 54% of international revenues in 2018 (vs 23.7% in 2000)
 - 6.1% sales CAGR in the last 10 years;
 - 22.4% of EBITDA margin in 2018;
 - 0.455 of Debt/Equity ratio;
 - Dividend policy: 31% average dividend pay out ratio over the last 10 years.



SOL Group – Geographic Presence



The Technical Gases Business





The Technical Gases Business

SOL Group operates in the technical gases business throughout the brand SOL

Production and distribution of Gases

A complete range of industrial gas (both atmospheric and non-atmospheric): medicinal, pure and special gases.

- Oxygen
- Nitrogen
- Argon
- Hydrogen
- Carbon dioxide
- Acetylene
- Nitrous oxide
- Gas mixtures

- Ultra high purity gases
- Medical gases
- Gaseous helium
- Liquid helium
- Refrigerating gases
- Electronics gases
- **◆** Ammonia
- Combustible gases
- ♦ LNG

Supply of plants, equipments, services and consultancy

Research, design, and construction of:

- Industrial gas production facilities
- Plant and equipment for gas utilization
- Services and consultancy

- Equipment for medical applications
- Equipment for cryogenic applications
- Deep freezing tunnels
- Oxygen burners
- Ozonisers


- Medical air plants
- On-site plants
- Welding machines and equipment




Technical Gases Business

Technical gases business (M€)	FY2018	FY2017	YoY
Sales	432	398	+ 8.4%
EBITDA	78	73	+ 6.6%
EBITDA %	18.0%	18.4%	- 0.4
Investments	52	51	- 1.2%

- In 2018 the division invested over the12% of its revenues.
- . 3.3% sales CAGR over the last 10 ys.







Technical Gases business

Market characteristics

- Resilient and growing market
- Margin protected thanks to high entry barriers
- Limited economic cycle demand dependence of each sales area
 - Broad variety and diversification of end-markets and applications
- Medium/long term contracts
- Local presence as a key factor


SOL

- High diversification of sales area:
 - . More than 50,000 clients served;
 - More than 90 different applications for technical gases
- Long term contracts with customers:
 - . Gas pipeline: up to 15 years;
 - Compressed gases: up to 5 years;
 - Cryogenic liquid gases: up to 3 years
- Strong local presence:
 - 25 countries, 38 primary transformation plants, 56 secondary transformation plants.




Resilience + Growth + Demand stability + Low risk level

Primary Production Sites (ASU, ...) AIR SEPARATION / LIQUEFACTION - OXYGEN, NITROGEN, ARGON **HYDROGEN - H2 CARBON DIOXYDE - CO2 ACETYLENE - C2H2 EIRE NITROUS OXYDE - N2O** India 39 primary production sites: units that produce gases from row materials (electric atmospheric energy, natural gas, calcium carbide and ammonium nitrate). Max reach-in area is 400 km. Morocco SOL




The Home Care Business





The Home Care Business

- In the second half of the eighties, SOL seized a new market diversification opportunity by entering into the Home-Care service sector, synergical with the technical gas sector.
- The Group works through the VIVISOL Group, which supplies technologically advanced home care services to patients for the treatment of chronic pathologies.
- VIVISOL manages the complete patient care from the delivery of medical equipment and drugs, performed by specialized home care professionals, to the provision of qualified medical and nursing services, as well as tele-monitoring services and emergency management.
- The company operates in 14 leading countries in Europe, in Brazil and Turkey, with over 60 offices employing over 2.200 employees and serving more than 400.000 patients daily.





The Home Care Business

Home care respiratory assistance

- Long term oxygen therapy
- Mechanical ventilation therapy
- Assistance to patients undergoing oxygen therapy during travels (VIVITRAVEL)
- Diagnosis and treatment of sleep disorder conditions

Other home care assistance

- Home care artificial nutrition
- Integrated home care services
- Remote monitoring and diagnosis of respiration conditions
- Palliative Care




Home Care Business

Hone Care business (M€)	FY2018	FY2017	YoY
Sales	431	388	+ 11.0%
EBITDA	109	94	+ 15.8%
EBITDA %	25.3%	24.2%	+ 1.1
Investments	43	41	+ 3.4%

- VIVISOL was able to grow 11%
 in 2018, with an EBITDA
 margin higher than 25%.
- The Group is continuing to invest significantly in this business.







Home Care Business



Key growth drivers:

- Aging population demographics
- Restructuring of Health Care Systems through de-hospitalization and home care
- Developments in portable medical technologies
- Better quality of life for Patients at home
- Increasing of respiratory and chronic pathologies





Home Care - VIVISOL branches




Home Care Business





The Hydro Energy Business





The Hydro Energy Business

- Leveraging on its core business development in the Eastern Europe, SOL entered into the Hydro-Energy sector.
- The industrial gas sector, is one of the most energy intensive one. This characteristic supported the Group decision to invest in the Hydro-Energy sector in order to enjoy synergies with its Industrial Gases Business.





Currently the company owns and operates 5 hydro-electric power plants in Slovenia (about 50 Million KWh/year), 2 plants in Albania (about 25 Million KWh/year); 4 plants in Macedonia (about 35 Million KWh/year); 4 plants in Bosnia (about 6 Million KWh/year).



The Biotechnology Business





The Biotechnology Business


- SOL Group is active in supplying biotechnological equipment and services to hospitals, clinics and laboratories (cryobanks, cellfactories, cryomanagement, cryotransportation)
- With BIOTECHSOL is active in the area of tissue and stem cells banking and biological tissues transportation.
- With the acquisition of the majority of DIATHEVA, SOL Group is active in drug discovery and drug delivery (recombinant monoclonal antibodies), molecular diagnostic, GMP production of recombinant proteins








SOL Group: 30 years Turnover (1988-2018)



SOL Group: consolidated results (2008 – 2018)




10 years net profit and dividend growth

NET PROFIT

DPS - Dividend Yield





10Y AVERAGE PAY-OUT RATIO 31%



International Expansion

10 years sales outside Italy 2008-2018




SOL is focused on its international expansion:

- The Group started its operations in Italy where it currently has 15 primary production sites.
- In 2018 the Group is present in 29 countries.
- In 2018 the non-domestic sales exceeded the Italian sales (54.3% / 45.7%).



Capital Expenditures (2008-2018)


10 years of Capex on sales 2008-2018



High annual investments

- The Group every year invest about 14% of its revenues;
 - The Sol business require a high level of investments for long term growth options;
 - In 2018 almost the 65% of the Group investments was made outside Italy.

Shareholding information and market price



Source: Borsa Italiana

Outstanding Shares

- 90.700.000 ordinary shares
- par value: 0,52

Shareholding Structure

- Fumagalli and Annoni families 60%
- Main Institutional Investors:
 - Tweedy Brown 7,346%
 - J O Hambro 4,914%
 - . azValor 5,178%



